Greco Luana, Rubbino Federica, Ferrari Clarissa, Cameletti Michela, Grizzi Fabio, Bonelli Fabrizio, Malesci Alberto, Mazzone Massimiliano, Ricciardiello Luigi, Laghi Luigi
Laboratory of Molecular Gastroenterology, IRCCS Humanitas Research Hospital, Milan, Italy.
Research and Clinical Trials Office, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.
Gut Microbiome (Camb). 2025 Apr 8;6:e5. doi: 10.1017/gmb.2025.3. eCollection 2025.
Colorectal cancer (CRC) represents a relevant public health problem, with high incidence and mortality in Western countries. CRC can occur as sporadic (65%-75%), common familial (25%), or as a consequence of an inherited predisposition (up to 10%). While unravelling its genetic basis has been a long trip leading to relevant clinical implementation over more than 30 years, other contributing factors remain to be clarified. Among these, micro-organisms have emerged as critical players in the development and progression of the disease, as well as for CRC treatment response. () has been associated with CRC development in both pre-clinical models and clinical settings. are core members of the human oral microbiome, while being less prevalent in the healthy gut, prompting questions about their localization in CRC and its precursor lesions. This review aims to critically discuss the evidence connecting with CRC pathogenesis, its molecular subtypes and clinical outcomes.
结直肠癌(CRC)是一个重大的公共卫生问题,在西方国家发病率和死亡率都很高。CRC可散发性发生(65%-75%)、常见家族性发生(25%),或由遗传易感性导致(高达10%)。虽然揭示其遗传基础是一段漫长的历程,在30多年间带来了相关临床应用,但其他促成因素仍有待阐明。其中,微生物已成为该疾病发生发展以及CRC治疗反应的关键因素。()在临床前模型和临床环境中均与CRC发生有关。()是人类口腔微生物群的核心成员,而在健康肠道中较少见,这引发了关于它们在CRC及其前驱病变中的定位问题。本综述旨在批判性地讨论将()与CRC发病机制、分子亚型和临床结果相联系的证据。
Gut Microbiome (Camb). 2025-4-8
mBio. 2025-4-9
Front Cell Infect Microbiol. 2022
Oncol Lett. 2019-8
Front Cell Infect Microbiol. 2020
Rev Gastroenterol Mex (Engl Ed). 2022
N Engl J Med. 2024-3-14
N Engl J Med. 2024-3-14
J Exp Clin Cancer Res. 2023-9-9